A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms FREEDOM-Ev
- Sponsors United Therapeutics Corporation
- 24 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
- 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2018.
- 14 Nov 2016 Planned number of patients changed from 610 to 850.